HC Wainwright Forecasts Increased Earnings for GH Research

Key Points

• HC Wainwright has raised its FY2029 earnings per share estimate for GH Research PLC from $0.13 to $0.19 and maintains a "Buy" rating with a target price of $40.00.
• Despite these optimistic projections, the consensus estimate for GH Research's current full-year earnings stands at a loss of ($0.80) per share.
• The company's stock has experienced significant trading volume, reaching $12.31 recently, and it has a market cap of $640.49 million.

GH Research PLC (NASDAQ:GHRS - Free Report) - Investment analysts at HC Wainwright boosted their FY2029 EPS estimates for GH Research in a report issued on Monday, August 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.19 per share for the year, up from their previous estimate of $0.13. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

Several other equities analysts have also recently commented on GHRS. Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Guggenheim cut their target price on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Cantor Fitzgerald started coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and set a $39.00 price target on shares of GH Research in a research report on Tuesday, June 24th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

GH Research Stock Performance

GH Research stock traded up $0.17 during midday trading on Wednesday, hitting $12.31. 10,393 shares of the company's stock were exchanged, compared to its average volume of 341,305. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The stock has a 50-day moving average price of $13.90 and a two-hundred day moving average price of $12.10. The company has a market cap of $640.49 million, a P/E ratio of -16.63 and a beta of 0.98.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07.

Institutional Trading of GH Research

A number of hedge funds have recently made changes to their positions in GHRS. Cormorant Asset Management LP boosted its position in shares of GH Research by 238.8% in the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock worth $22,165,000 after purchasing an additional 1,416,439 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of GH Research during the first quarter valued at approximately $8,272,000. Lynx1 Capital Management LP increased its position in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of GH Research during the first quarter valued at approximately $5,018,000. Finally, RA Capital Management L.P. increased its position in shares of GH Research by 3.9% during the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock valued at $76,599,000 after acquiring an additional 257,959 shares in the last quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.